EARLY EXPERIENCE WITH CYTOREDUCTION AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY AT THE NATIONAL INSTITUTE OF CANCER IN ECUADOR diego.a.zambrano@solca.med.ec

 

EARLY EXPERIENCE WITH CYTOREDUCTION AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY AT THE NATIONAL INSTITUTE OF CANCER IN ECUADOR

6

Ecuador

Oral or Poster

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has improved outcomes for patients with peritoneal surface malignancies (PSM). We present the experience from a newly developed peritoneal surface malignancy program in Ecuador.

Single center retrospective study performed from our CRS/HIPEC database for management of PSM from February 2023 to July 2025. Validation was made in tumor board considering performance status, no extra-peritoneal disease, preoperative imaging or diagnostic laparoscopy. Follow-up and outcome data were available for all patients who underwent CRS/HIPEC. Frequencies were characterized using the median (range) or mean (standard deviation). Kaplan-Meier method was used to calculate overall survival (OS) and progression-free survival (PFS). Statistical analysis was performed using SPSS software, version 25 (IBM Corporation, Armonk, NY).

Total of 49 patients underwent CRS/HIPEC; 67% were female (n=33), median age of 54 years (range: 28–77). Primary pathology included: colon (41%, n=20), ovary (26%, n=13), appendix (26%, n=13), gastric (4%, n=2), and other (3%, n=1). The median peritoneal cancer index (PCI) was 18 (range, 1–39) and 95% underwent complete cytoreduction (CCR 0/1). Median hospital length of stay was 10 days (range, 6–35 days). The 30-day mortality was 2% (n=1). The OS for all etiologies was 25 months (95% CI 22.7-27.7). PFS for ovary was 23 months (95% CI, 19.4-26.5), appendix 20 months (95% CI, 14.2-27.1), colon 19 months (95% CI, 15.2-23), and stomach 8 months, Log-Rank 0.21.

Short-term outcomes observed after CRS/HIPEC in our program are consistent with published higher volume center experience.